LifeMD's Q2 results reveal pressure from higher customer acquisition costs.
ByAinvest
Friday, Aug 29, 2025 10:06 am ET1min read
LFMD--
LifeMD's shares plummeted $5.31 (-44%) on August 6, 2025, after the company reported missing consensus GAAP EPS and revenue estimates. The earnings call revealed higher-than-expected refund rates and elevated customer acquisition costs, particularly in the RexMD segment, which focuses on men's health [1].
The investigation, led by Hagens Berman partner Reed Kathrein, centers on LifeMD's May 6, 2025, earnings call, where the company raised its full-year 2025 revenue and adjusted EBITDA guidance. The complaint alleges that LifeMD made false and misleading statements while failing to disclose crucial information, including rising customer acquisition costs and costs related to the sale of obesity drugs [1].
KeyBanc analyst, in a recent report, criticized LifeMD's management for its "overly optimistic" guidance and "lack of transparency" regarding operational challenges. The analyst advised investors to exercise caution and closely monitor the company's future earnings reports [2].
Investors who purchased LifeMD securities between May 7, 2025, and August 5, 2025, are encouraged to submit their losses and contact Hagens Berman or Johnson Fistel, PLLP for further information. The lead plaintiff deadline is October 27, 2025 [1, 2].
References:
[1] https://www.marketscreener.com/news/lifemd-inc-lfmd-hit-with-securities-class-action-after-shares-crash-44-on-q2-2025-earnings-surp-ce7c50dfd18df621
[2] https://www.globenewswire.com/news-release/2025/08/28/3141185/0/en/LifeMD-Inc-Shareholders-Who-Lost-Money-on-Their-Investment-are-Encouraged-to-Contact-Johnson-Fistel-about-the-Class-Action-Lawsuit.html
• LifeMD under investigation for securities fraud and unlawful practices. • Company reports higher customer acquisition costs in Q2 2025. • RexMD platform focused on men's health. • KeyBanc analyst criticizes LifeMD's management.
LifeMD Inc. (LFMD), a company focused on virtual obesity care, is currently under investigation for potential securities fraud and unlawful practices. The probe, initiated by prominent shareholder rights firm Hagens Berman, follows the company's disappointing Q2 2025 financial results and subsequent stock price crash [1].LifeMD's shares plummeted $5.31 (-44%) on August 6, 2025, after the company reported missing consensus GAAP EPS and revenue estimates. The earnings call revealed higher-than-expected refund rates and elevated customer acquisition costs, particularly in the RexMD segment, which focuses on men's health [1].
The investigation, led by Hagens Berman partner Reed Kathrein, centers on LifeMD's May 6, 2025, earnings call, where the company raised its full-year 2025 revenue and adjusted EBITDA guidance. The complaint alleges that LifeMD made false and misleading statements while failing to disclose crucial information, including rising customer acquisition costs and costs related to the sale of obesity drugs [1].
KeyBanc analyst, in a recent report, criticized LifeMD's management for its "overly optimistic" guidance and "lack of transparency" regarding operational challenges. The analyst advised investors to exercise caution and closely monitor the company's future earnings reports [2].
Investors who purchased LifeMD securities between May 7, 2025, and August 5, 2025, are encouraged to submit their losses and contact Hagens Berman or Johnson Fistel, PLLP for further information. The lead plaintiff deadline is October 27, 2025 [1, 2].
References:
[1] https://www.marketscreener.com/news/lifemd-inc-lfmd-hit-with-securities-class-action-after-shares-crash-44-on-q2-2025-earnings-surp-ce7c50dfd18df621
[2] https://www.globenewswire.com/news-release/2025/08/28/3141185/0/en/LifeMD-Inc-Shareholders-Who-Lost-Money-on-Their-Investment-are-Encouraged-to-Contact-Johnson-Fistel-about-the-Class-Action-Lawsuit.html
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet